NASDAQ:TCRT

Alaunos Therapeutics Stock Insider Trading

Healthcare > Biotechnology

Buy TCRT

*Your capital is at risk

$2.62

-0.130 (-4.73%)

At Close: Jun 03, 2026

Alaunos Therapeutics Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be positive at 95.74. In total, the insiders bought 5.72M and sold 142.03K TCRT shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	95.74
● Buy	5.72M shares
● Sell	142.03K shares
94% Buy Activity Weak Positive Correlation
Buy Signal High Confidence Apr 29, 2026 Analysis Breakdown: Strongly supported by a very high Insider Power Score of 95.74. Confidence increased due to high data reliability score of 100. Supported by overwhelming buy-side pressure (94% buys).

Historical Insider Trades

Date	Type	Person	Role	Amount
May 22, 2026 Buy	Common Stock A-Award	Weis Holger Chief Executive Officer	CEO / President	3 700 Value: $9K
Apr 29, 2026 Buy	Common Stock A-Award	Postma Robert W Director	Director	6 274 Value: $16.2K
Apr 29, 2026 Buy	Common Stock A-Award	Vieser Jaime Director	Director	6 515 Value: $16.9K
Apr 29, 2026 Buy	Common Stock A-Award	Jerman Michael Allen Director	Director	6 032 Value: $15.6K
Jan 12, 2026 Buy	Common Stock A-Award	Vieser Jaime Director	Director	5 839 Value: $16.9K
Jan 12, 2026 Buy	Common Stock A-Award	Postma Robert W Director	Director	5 622 Value: $16.2K
Jan 12, 2026 Buy	Common Stock A-Award	Jerman Michael Allen Director	Director	5 406 Value: $15.6K
Nov 21, 2025 Buy	Common Stock A-Award	Vieser Jaime Director	Director	5 340 Value: $16.9K
Nov 21, 2025 Buy	Common Stock A-Award	Jerman Michael Allen Director	Director	4 183 Value: $13.2K
Nov 21, 2025 Buy	Common Stock A-Award	Postma Robert W Director	Director	5 142 Value: $16.2K
Aug 18, 2025 Buy	Common Stock A-Award	Groenewald Ferdinand Vice President Of Finance	CEO / President	10 775 Value: $25.1K
Aug 18, 2025 Buy	Employee Stock Option (right to buy) A-Award	Groenewald Ferdinand Vice President Of Finance	CEO / President	4 000 Value: $9K
Aug 18, 2025 Buy	Employee Stock Option (right to buy) A-Award	Weis Holger Chief Executive Officer	CEO / President	13 676 Value: $31.7K
Aug 18, 2025 Buy	Employee Stock Option (right to buy) A-Award	Weis Holger Chief Executive Officer	CEO / President	13 676 Value: $31.7K
Aug 18, 2025 Buy	Common Stock A-Award	Groenewald Ferdinand Vice President Of Finance	CEO / President	10 775 Value: $25.1K
Aug 18, 2025 Buy	Employee Stock Option (right to buy) A-Award	Groenewald Ferdinand Vice President Of Finance	CEO / President	4 000 Value: $9K
Jul 15, 2025 Buy	Employee Stock Option (right to buy) A-Award	Jerman Michael Allen Director	Director	10 000 Value: $34.0K
Jul 15, 2025 Buy	Employee Stock Option (right to buy) A-Award	Jerman Michael Allen Director	Director	3 200 Value: $10.9K
Jul 15, 2025 Buy	Common Stock J-Other	Jerman Michael Allen Insider	Other	0 Value: $0
Jul 15, 2025 Buy	Common Stock J-Other	Jerman Michael Allen Insider	Other	0 Value: $0
Jul 15, 2025 Buy	Employee Stock Option (right to buy) A-Award	Jerman Michael Allen Director	Director	3 200 Value: $10.9K
Jul 15, 2025 Buy	Employee Stock Option (right to buy) A-Award	Jerman Michael Allen Director	Director	10 000 Value: $34.0K
Jul 03, 2025 Buy	Common Stock A-Award	Postma Robert W Director	Director	4 050 Value: $20.3K
Jul 03, 2025 Buy	Employee Stock Option (right to buy) A-Award	Postma Robert W Director	Director	6 400 Value: $32.0K
Jul 03, 2025 Buy	Common Stock A-Award	Vieser Jaime Director	Director	3 400 Value: $17.0K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT ALAUNOS THERAPEUTICS, INC.

Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive TCR engineered T-cell therapies. It develops TCR Library, which is in Phase I/II clinical trial for ten TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers; hunTR, a human neoantigen T-cell receptor platform; and mbIL-15 to...

Read Full Profile Here